Key result
Statins effectively reduce recurrent stroke and cardiovascular events in secondary prevention.
Why the study?
The efficacy of statin treatment in secondary prevention of stroke and cardiovascular events was demonstrated by the 2006 SPARCL trial, but its role in young people after ischemic stroke remains to be clarified.
Key points are not available for this paper at this time.
Design
Other
May refine post-stroke risk stratification; leaves open whether apoE measurement should guide therapy.
The 2006 SPARCL trial was the first large randomized trial that conclusively demonstrated the efficacy of statin treatment in the secondary prevention of stroke and cardiovascular events in patient...
No takes yet. Share an insight, caveat, or question.
Putaala et al. (2012) studied this question. Statin treatment conclusively demonstrated efficacy in the secondary prevention of stroke and cardiovascular events.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: